Manish Pal's questions to XBiotech (XBIT) leadership • Q2 2016
Question
Manish Pal of MHP Capital inquired about the timeline for the European disposition of Xilonix, seeking confirmation of a Q4 date. He also asked for clarification on the shift from an expedited to a standard review process and questioned the company's pipeline for new partnership opportunities.
Answer
Founder, President & CEO John Simard confirmed the Q4 timeline for the European disposition. He explained the review process change was due to a different regulatory group handling the registration, which needed time to review the novel study design. Regarding partnerships, Simard noted that several discussions are ongoing for strategic fits that support the company's long-term, self-sufficient model.